Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > PharmaNova, Inc. Forms Strategic Alliance With Taiwan-Based Orient Europharma

Abstract:
PharmaNova Inc. today announced that it has formed a strategic alliance and collaboration with Orient Europharma Company Ltd. (Taiwan OTC: 4120) (OEP) of Taiwan, R.O.C. In this two-way relationship, it is intended that OEP will be PharmaNova's exclusive manufacturing and commercialization partner for future PharmaNova products in the core territories of Taiwan, Hong Kong, Singapore, Malaysia, the Philippines and S. Korea served by OEP, and that OEP will manufacture and supply PharmaNova products to future marketing partners in the broader Asia-Pacific region. OEP has an extensive technology base for the controlled release of pharmaceuticals, both orally and by transdermal administration, that is highly complementary to PharmaNova's platform Medisperse(TM) nanoparticle and Surface Enhancement (SET(TM)) technologies.

PharmaNova, Inc. Forms Strategic Alliance With Taiwan-Based Orient Europharma

ROCHESTER, NY | Posted on March 21st, 2007

As part of the arrangement, OEP will address the scale up of the nanoparticle technology and, together, OEP and PharmaNova intend to become world leaders in the application and manufacturing of nanoparticle-based pharmaceuticals. The companies will collaborate on the application of both companies' platform technologies to complete mutually selected new product opportunities, for development and commercialization worldwide utilizing OEP's new manufacturing facilities in Taiwan. PharmaNova President Rodney Brown said, "We are very impressed with OEP's excellent product manufacturing and commercialization capabilities and look forward to a long and mutually rewarding relationship."

OEP has an extensive portfolio of products both in development and already in the marketplace, and PharmaNova will support OEP in expanding the regional commercialization of its products throughout Asia-Pacific and through partnerships in Latin America, Europe and U.S. Central to the collaboration is the exclusive development and commercialization of Xenolev-CR(TM) by OEP for Asia Pacific territories. Xenolev-CR(TM) is PharmaNova's proprietary non-hormonal treatment for hot flashes associated with the menopause and other conditions. Mr. Peter Tsai, president and chairman of OEP, said, "We are very excited about this partnership with PharmaNova as it will allow OEP to expand the geographical scope of our business activities beyond the immediate Asia Pacific region by contributing our expertise in product development and utilizing our new state of the art manufacturing facilities."

####

About PharmaNova, Inc.
PharmaNova Inc. ( ' http://www.pharmanovaco.com ' ) is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using proprietary Medisperse(TM) nanoparticle and other formulation technologies. PharmaNova's revenue base is generated through partnering and licensing strategies involving low-risk, fast to market products and commercialization partners worldwide. PharmaNova's current focus is on extraordinary value products in Women's Health and adjacent areas, including a non-hormonal treatment for menopausal hot flashes, anti-viral agents and cancer chemotherapeutics.

Orient Europharma Co. Ltd., ( ' http://www.OEP.com.tw ' ) is an international publicly traded pharmaceutical and nutritional company based in Taipei, Taiwan, R.O.C. traded over the counter under symbol "OEP." OEP specializes in research and marketing of innovative, niche-oriented pharmaceuticals, with a strong franchise in oncology, nutritional and food supplements, dermo-cosmetics and consumer healthcare products. OEP has a well-established marketing base in numerous Asia-Pacific countries with subsidiaries in Singapore, Malaysia, Hong Kong, Philippines and China, and it is poised for significant growth.

For more information, please click here

Contacts:
Rodney Brown
PharmaNova, Inc.
1-585-214-0590

Copyright © EWORLDWIRE™

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Announcements

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Alliances/Partnerships/Distributorships

Nature inspires a greener way to make colorful plastics July 30th, 2014

SouthWest NanoTechnologies Names NanoSperse as A SWeNT Certified Compounder July 29th, 2014

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

A*STAR and industry form S$200M semiconductor R&D July 25th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE